Pyxis Oncology, Inc.
Company Information
Industry Pharmaceutical Preparations
SIC Code 2834
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 321 HARRISON AVENUE, BOSTON, MA, 02118
Mailing Address 321 HARRISON AVENUE, BOSTON, MA, 02118
Phone (617) 221-9059
Fiscal Year End 1231
EIN 831160910
Financial Overview
FY2024 FY
$16.15M
Revenue
$173.73M
Total Assets
$160.82M
Stockholders' Equity
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| SCHEDULE 13G/A Passive ownership amendment | February 9, 2026 | View on SEC |
| 8-K Current report of material events | February 6, 2026 | View on SEC |
| 4 Insider stock transaction report | February 5, 2026 | View on SEC |
| 8-K Current report of material events | December 18, 2025 | View on SEC |
| S-3 Shelf registration for future offerings | November 26, 2025 | View on SEC |
| 10-Q Quarterly financial report | November 3, 2025 | View on SEC |
| 8-K Current report of material events | November 3, 2025 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | October 14, 2025 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | September 23, 2025 | View on SEC |
| 10-Q Quarterly financial report | August 14, 2025 | View on SEC |
Material Events
8-K Leadership Change February 6, 2026
High Impact
- Interim CEO Tom Civik has a strong track record, including guiding Five Prime Therapeutics to acquisition by Amgen.
- Civik's compensation is heavily incentivized for successful financing or strategic transactions, signaling the Board's immediate priority.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.